Exenatide Capsule Gleans Patent in Israel


Exenatide AcetateKnown as the brand name Byetta in the United States, which is marketed by AstraZeneca, Exenatide is a GLP-1 analog that is currently offered as an injectable treatment for type 2 diabetes. In mid-January 2015 Oramed Pharmaceuticals was granted a patent in Israel for the oral administration of Exenatide. As an effectual therapy for patients with type 2 diabetes, the advent of this Exenatide capsule is exciting for both patients and practitioners. Exenatide works by producing insulin release at increased glucose levels, which creates a feeling of satiety in patients, subsequently causing a reduction in food intake. This extra bonus of eliciting a reduction in dietary consumption makes Exenatide an ideal treatment for weight loss and weight control, as well as for insulin control. The injectable form of Exenatide has been helpful for patients, but challenging in terms of medication adherence. Many patients dislike using an injectable form of medication daily, so the novel Exenatide capsule is sure to create an optimal form of administration.

Exenatide is also being examined as a potential therapy for patients with Parkinson’s disease. In May 2014 a “Proof of Concept” trial was shared from the Sobell Department of Motor Neuroscience at the UCL Institute of Neurology in London. Basing patient results on a year’s worth of sound data from patients with Parkinson’s disease who had been administered Exenatide for a full year (May 2013-May 2014), an analysis of data showed noteworthy improvements in patients who received Exenatide. Researchers involved in this study cite the neuroprotective benefits of Exenatide, particularly for neuroplasticity. The side effect profile of Exenatide is also a plus for patients, with a small minority of trial participants experiencing mild nausea. The aforementioned study involved 44 patients with moderate to severe Parkinson’s disease. Approximately 20 of the patients received Exenatide in addition to their usual best in care treatment program, and 24 patients were given the placebo alongside best in care therapy. At the one year mark significantly clinical differences were apparent between the groups, with meaningful motor and cognitive differences gleaned from the patients group who received Exenatide. Even at the 14 month mark, when patients who had received Exenatide were taking a holiday from this medication the differences were still widely apparent between both the groups. Researchers utilized the Mattis Dementia Rating scale, as well as a blinded MDS-UPDRS motor subscale evaluation for the patients. The participants who were administered Exenatide had advantages of 5.6 on the blinded MDS-UPDRS motor subscale and 5.3 points on the Mattis Dementia Rating scale as compared to the placebo group. This information is hopeful for the future use of Exenatide for the treatment of not only type 2 diabetes, but also potentially for patients with Parkinson’s disease.

Whether it is injectable or oral Exenatide, LGM Pharma is available to assist clients as a supplier/distributor of the Exenatide CAS# 141758-74-9 API or the Exenatide Acetate CAS# 141732-76-5 API for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share: